Statistics at a Glance
At a Glance
|Year||Rate of New Cases — SEER 8||Rate of New Cases — SEER 12||Death Rate — SEER 8 Incidence-Based Mortality||5-Year Relative Survival — SEER 8|
|Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend||Observed||Modeled Trend|
New cases come from SEER 12. Deaths come from SEER 8 Incidence-Based Mortality.
All Races, Both Sexes. Rates are Age-Adjusted.
Modeled trend lines were calculated from the underlying rates using the Joinpoint Trend Analysis Software.
The 2020 incidence rate is displayed but not used in the fit of the trend line(s). Impact of COVID on SEER Cancer Incidence 2020 data
New cases are also referred to as incident cases in other publications. Rates of new cases are also referred to as incidence rates.
Rate of New Cases and Deaths per 100,000: The rate of new cases of chronic lymphocytic leukemia/small lymphocytic lymphoma was 4.4 per 100,000 men and women per year. The death rate was 0.8 per 100,000 men and women per year. These rates are age-adjusted and based on 2016–2020 cases and deaths.
- Mortality statistics for chronic lymphocytic leukemia/small lymphocytic lymphoma are based on SEER Incidence-Based Mortality.
How Many People Survive 5 Years Or More after Being Diagnosed with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma?
Relative survival is an estimate of the percentage of patients who would be expected to survive the effects of their cancer. It excludes the risk of dying from other causes. Because survival statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. No two patients are entirely alike, and treatment and responses to treatment can vary greatly.
Based on data from SEER 22 (Excluding IL/MA) 2013–2019. Gray figures represent those who have died from chronic lymphocytic leukemia/small lymphocytic lymphoma. Green figures represent those who have survived 5 years or more.
SEER 22 (Excluding IL/MA) 2013–2019
Who Gets This Cancer?
The rate of new cases of chronic lymphocytic leukemia/small lymphocytic lymphoma was 4.4 per 100,000 men and women per year based on 2016–2020 cases, age-adjusted.
|Non-Hispanic American Indian/Alaska Native||3.6|
|Non-Hispanic Asian/Pacific Islander||1.7|
|Non-Hispanic American Indian/Alaska Native||Not Shown, <16 cases|
|Non-Hispanic Asian/Pacific Islander||0.8|
SEER 22 2016–2020, Age-Adjusted
|Age Range||Percent of New Cases|
Chronic lymphocytic leukemia/small lymphocytic lymphoma is most frequently diagnosed among people aged 65–74.
SEER 22 2016–2020, All Races, Both Sexes
Trends in Rates
Changes Over Time
Keeping track of new cases, deaths, and survival over time (trends) can help scientists understand whether progress is being made and where additional research is needed to address challenges, such as improving screening or finding better treatments.
Using statistical models for analysis, age-adjusted rates for new chronic lymphocytic leukemia/small lymphocytic lymphoma cases have been falling on average 1.4% each year over 2010–2019. Age-adjusted death rates have been stable over 2011–2020. 5-year relative survival trends are shown below.
Interactive Statistics with SEER*Explorer
- Create custom graphs and tables
- Download data and images
- Share links to results
SEER*Explorer is an interactive website that provides easy access to a wide range of SEER cancer statistics. It provides detailed statistics for a cancer site by gender, race, calendar year, age, and for a selected number of cancer sites, by stage and histology.Explore Additional Non-Hodgkin Lymphoma Statistics
More About This Cancer
Figure: This picture shows lymph nodes above and below the diaphragm. It also shows the lymph vessels, tonsils, thymus, and spleen.
Lymphoma is cancer that begins in cells of the lymph system. The lymph system is part of the immune system, which helps the body fight infection and disease. Because lymph tissue is found all through the body, lymphoma can begin almost anywhere.
The two main types of lymphoma are Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). These can occur in both children and adults.
There are many different types of NHL that form from different types of white blood cells (B-cells, T-cells, NK cells). Most types of NHL form from B-cells. NHL may be indolent (slow-growing) or aggressive (fast-growing). The most common types of NHL in adults are diffuse large B-cell lymphoma, which is usually aggressive, and follicular lymphoma, which is usually indolent.
Here are some resources for learning more about non-Hodgkin lymphoma.
- More about risk factors for non-Hodgkin lymphoma
- More about symptoms and diagnosis of non-Hodgkin lymphoma
- More about treatment options for non-Hodgkin lymphoma
- More about clinical trials
- More about cancer prevention
All statistics in this report are based on statistics from SEER and the Centers for Disease Control and Prevention's National Center for Health Statistics. Most can be found within SEER*Explorer.
All material in this report is in the public domain and may be reproduced or copied without permission; citation as to source, however, is appreciated.
SEER Cancer Stat Facts: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/statfacts/html/cllsll.html
These stat facts focus on population statistics that are based on the U.S. population. Because these statistics are based on large groups of people, they cannot be used to predict exactly what will happen to an individual patient. To see tailored statistics, browse SEER*Explorer. To see statistics for a specific state, go to the State Cancer Profiles.
The statistics presented in these stat facts are based on the most recent data available, most of which can be found in SEER*Explorer. In some cases, different year spans may be used.
Estimates of new cases and deaths for 2023 are projections made by the American Cancer Society (ACS), based on earlier reported data.
Cancer is a complex topic. There is a wide range of information available. These stat facts do not address causes, symptoms, diagnosis, treatment, follow-up care, or decision making, although links are provided to information in many of these areas.